Immunis Inc. announced new preclinical research indicating that its investigational therapeutic approach promoted body fat loss, reduced liver steatosis and fibrosis, and increased lean muscle mass in aged animal models. According to the company, the findings suggest potential for treating age-related metabolic and degenerative conditions.
The company said the study was conducted to evaluate how its proprietary secretome-based treatment affects body composition, liver function, and overall metabolic health. Results reportedly demonstrated improvements in key physiological markers associated with aging, including enhanced muscle strength and reduced fat accumulation.
According to Immunis, the treatment’s effects were accompanied by a reversal of fatty liver disease characteristics, including a decrease in hepatic fat content and fibrotic tissue. The company claims these outcomes indicate its therapeutic platform may help restore metabolic balance and organ function in aging populations.
Immunis stated that its therapeutic technology is derived from allogeneic secretomes containing proteins and factors involved in tissue regeneration and immune modulation. The company added that its approach aims to address multiple pathways of age-associated decline, rather than focusing on single disease targets.
The company said the findings contribute to its broader clinical development program focused on combating muscle atrophy, metabolic dysfunction, and systemic inflammation. Immunis noted that it plans to continue advancing research on its regenerative therapy platform as it explores potential human applications in future studies.
